Search

Viking Therapeutics Inc

Cerrado

SectorSanidad

32.01 -2.11

Resumen

Variación precio

24h

Actual

Mínimo

31.78

Máximo

32.69

Métricas clave

By Trading Economics

Ingresos

30M

-128M

BPA

-1.1

Empleados

65

EBITDA

30M

-128M

Dividendos

By Acuity

Próximas Ganancias

21 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

19M

4.1B

Apertura anterior

34.12

Cierre anterior

32.01

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

144 / 339 Clasificación en Healthcare

Viking Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 sept 2026, 23:11 UTC

Viking Therapeutics Inc shares are higher in after-market trading, recovering from earlier lows despite being below the 20-day moving average. No specific news was identified.

2 sept 2026, 19:46 UTC

Viking Therapeutics Inc shares are lower today, pulling back from earlier session highs amid broader market concerns over rising U.S. Treasury yields.

31 ago 2026, 19:36 UTC

Viking Therapeutics shares are higher today, despite earlier pressure, amid broader market dynamics influenced by rising interest rate expectations following comments from the Fed.

29 ago 2026, 00:01 UTC

Viking Therapeutics Inc shares rose in after-market trading, reflecting a notable increase since Friday's close, despite no specific news driving the movement.

28 ago 2026, 23:36 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, gaining since Friday's close, despite fluctuations and remaining below the 20-day moving average.

27 ago 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher in after-market hours following notable volatility during the session, despite no specific news to explain the movement.

26 ago 2026, 19:16 UTC

Viking Therapeutics Inc shares are higher today, though no specific news was identified to explain the price movement. The stock remains above its 20-day moving average.

25 ago 2026, 23:16 UTC

Viking Therapeutics shares are lower in after-market hours amid broader market volatility, with falling oil prices and geopolitical developments affecting investor sentiment.

24 ago 2026, 19:56 UTC

Social Media

Viking Therapeutics Inc shares are lower today, continuing a decline since Friday. Social media discussions highlight anticipation for upcoming data before Labor Day.

20 ago 2026, 20:06 UTC

Macro Event
Social Media

Viking Therapeutics Inc shares are lower, impacted by labor market data and heightened volatility, despite social media discussions suggesting potential recovery from a clinical trial.

19 ago 2026, 23:16 UTC

Viking Therapeutics Inc shares are higher in after-market hours, reflecting a gain since Wednesday's close and remaining above the 20-day moving average.

18 ago 2026, 19:16 UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17 ago 2026, 23:06 UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14 ago 2026, 23:06 UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13 ago 2026, 23:16 UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12 ago 2026, 23:26 UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7 ago 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6 ago 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5 ago 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 ago 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 ago 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 jul 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 jul 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 jul 2026, 23:21 UTC

Social Media
News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 jul 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 jul 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 jul 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 jul 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 jul 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 jul 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Comparación entre iguales

Cambio de precio

Viking Therapeutics Inc previsión

Consenso

By TipRanks

Compra Fuerte

14 ratings

14

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

144 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat